Stifel analyst Parker Lane maintains Everbridge (NASDAQ:EVBG) with a Hold and raises the price target from $32 to $38.
Ocuphire Announces Late Breaking Presentation On APX3330 ZETA-1 Clinical Data At American Diabetes Association Annual Conference
Ocuphire Pharma, Inc. (NASDAQ:OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of retinal and refractive eye disorders, today announced